The Lancet Regional Health: Western Pacific最新文献

{"title":"Advancing social prescribing in Singapore: an update on progress","authors":"Jojo Qian Hui Nah ,&nbsp;Sharna Si Ying Seah ,&nbsp;Lian Leng Low ,&nbsp;Kheng Hock Lee","doi":"10.1016/j.lanwpc.2024.101159","DOIUrl":"10.1016/j.lanwpc.2024.101159","url":null,"abstract":"<div><p>In 2019, SingHealth Community Hospitals (SCH) introduced Social Prescribing (SP) program to support patients in transitioning back to the community after hospitalization, which involves personalized care plans developed by Wellbeing Coordinators (WBCs) to connect patients with relevant community resources. With the recent launch of the nation-wide ‘Healthier SG’ initiative, a population health strategy in Singapore aimed at enabling individuals to prevent and manage chronic diseases, it is important to provide an update on our program's recent developments. This includes creating a living asset map, updating outcome assessment tools, organizing training sessions to enhance the skills SP practitioners, and establishing the Singapore Community of Practice in Social Prescribing (SCOMP).</p></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101159"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001536/pdfft?md5=4ad280865dad276cde1c28b120519522&pid=1-s2.0-S2666606524001536-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141963051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Global epidemiology of severe fever with thrombocytopenia syndrome virus in human and animals: a systematic review and meta-analysis” [The Lancet Regional Health - Western Pacific, Volume: 48 (2024) 101133]","authors":"Haoliang Cui ,&nbsp;Shijing Shen ,&nbsp;Lin Chen ,&nbsp;Zhiyu Fan ,&nbsp;Qian Wen ,&nbsp;Yiwen Xing ,&nbsp;Zekun Wang ,&nbsp;Jianyi Zhang ,&nbsp;Jingyuan Chen ,&nbsp;Bin La ,&nbsp;Yujie Fang ,&nbsp;Zeping Yang ,&nbsp;Shuhan Yang ,&nbsp;Xiangyu Yan ,&nbsp;Shaojun Pei ,&nbsp;Tao Li ,&nbsp;Xiaoming Cui ,&nbsp;Zhongwei Jia ,&nbsp;Wuchun Cao","doi":"10.1016/j.lanwpc.2024.101174","DOIUrl":"10.1016/j.lanwpc.2024.101174","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101174"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001688/pdfft?md5=b4e77a605ed1cb436104d4be3403cc7d&pid=1-s2.0-S2666606524001688-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142021234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Context matters: physical activity in the Western Pacific region","authors":"The Lancet Regional Health – Western Pacific","doi":"10.1016/j.lanwpc.2024.101190","DOIUrl":"10.1016/j.lanwpc.2024.101190","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101190"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001846/pdfft?md5=573418bf6d4731feab650dcfa1f96135&pid=1-s2.0-S2666606524001846-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and cost-effectiveness of remote-delivered, online lifestyle therapy versus psychotherapy for reducing depression: results from the CALM non-inferiority, randomised trial","authors":"Adrienne O’Neil ,&nbsp;Joahna Perez ,&nbsp;Lauren M. Young ,&nbsp;Tayla John ,&nbsp;Megan Turner ,&nbsp;Dean Saunders ,&nbsp;Sophie Mahoney ,&nbsp;Marita Bryan ,&nbsp;Deborah N. Ashtree ,&nbsp;Felice N. Jacka ,&nbsp;Courtney Bruscella ,&nbsp;Megan Pilon ,&nbsp;Mohammadreza Mohebbi ,&nbsp;Megan Teychenne ,&nbsp;Simon Rosenbaum ,&nbsp;Rachelle Opie ,&nbsp;Meghan Hockey ,&nbsp;Lucija Peric ,&nbsp;Samantha De Araugo ,&nbsp;Khyati Banker ,&nbsp;Mary Lou Chatterton","doi":"10.1016/j.lanwpc.2024.101142","DOIUrl":"10.1016/j.lanwpc.2024.101142","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;p&gt;We conducted the first non-inferiority, randomised controlled trial to determine whether lifestyle therapy is non-inferior to psychotherapy with respect to mental health outcomes and costs when delivered via online videoconferencing.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;p&gt;An individually randomised, group treatment design with computer-generated block randomisation was used. Between May 2021–April 2022, 182 adults with a Distress Questionnaire-5 score = ≥8 (indicative depression) were recruited from a tertiary mental health service in regional Victoria, Australia and surrounds. Participants were assigned to six 90-min sessions over 8-weeks using group-based, online videoconferencing comprising: (1) lifestyle therapy (targeting nutrition, physical activity) with a dietitian and exercise physiologist (n = 91) or (2) psychotherapy (Cognitive Behavioural Therapy) with psychologists (n = 91). The primary outcome was Patient Health Questionnaire-9 (PHQ-9) depression at 8-weeks (non-inferiority margin ≤2) using Generalised Estimating Equations (GEE). Cost-minimisation analysis estimated the mean difference in total costs from health sector and societal perspectives. Outcomes were assessed by blinded research assistants using Computer Assisted Telephone Interviews. Results are presented per-protocol (PP) and Intention to Treat (ITT) using beta coefficients with 95% Confidence Intervals (CIs).&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Findings&lt;/h3&gt;&lt;p&gt;The sample was 80% women (mean: 45-years [SD:13.4], mean PHQ-9:10.5 [SD:5.7]. An average 4.2 of 6 sessions were completed, with complete data for n = 132. Over 8-weeks, depression reduced in both arms (PP: Lifestyle (n = 70) mean difference:−3.97, 95% CIs:−5.10, −2.84; and Psychotherapy (n = 62): mean difference:−3.74, 95% CIs:−5.12, −2.37; ITT: Lifestyle (n = 91) mean difference:−4.42, 95% CIs: −4.59, −4.25; Psychotherapy (n = 91) mean difference:−3.82, 95% CIs:−4.05, −3.69) with evidence of non-inferiority (PP GEE β:−0.59; 95% CIs:−1.87, 0.70, n = 132; ITT GEE β:−0.49, 95% CIs:−1.73, 0.75, n = 182). Three serious adverse events were recorded. While lifestyle therapy was delivered at lower cost, there were no differences in total costs (health sector adjusted mean difference: PP AUD$156 [95% CIs −$182, $611, ITT AUD$190 [95% CIs −$155, $651] ]; societal adjusted mean difference: PP AUD$350 [95% CIs:−$222, $1152] ITT AUD$ 408 [95% CIs −$139, $1157].&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Interpretation&lt;/h3&gt;&lt;p&gt;Remote-delivered lifestyle therapy was non-inferior to psychotherapy with respect to clinical and cost outcomes. If replicated in a fully powered RCT, this approach could increase access to allied health professionals who, with adequate training and guidelines, can deliver mental healthcare at comparable cost to psychologists.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Funding&lt;/h3&gt;&lt;p&gt;This trial was funded by the &lt;span&gt;Australian Medical Research Future Fund&lt;/span&gt; (&lt;span&gt;&lt;span&gt;GA133346&lt;/span&gt;&lt;/span&gt;) under its Covid-19 Mental Health Research Grant Sche","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101142"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001366/pdfft?md5=501a59b0063a5e118bdec8721f641dea&pid=1-s2.0-S2666606524001366-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variations in suicide rates among Australian male construction workers by country of birth","authors":"Tania L. King ,&nbsp;Ludmila Fleitas Alfonzo ,&nbsp;Anthony D. LaMontagne ,&nbsp;Humaira Maheen","doi":"10.1016/j.lanwpc.2024.101155","DOIUrl":"10.1016/j.lanwpc.2024.101155","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101155"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001494/pdfft?md5=bbd64a568bb00f3b62a142cc04bcf3f7&pid=1-s2.0-S2666606524001494-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141950165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to advocating for rigorous and multifactorial analyses in post-COVID cognitive research","authors":"Yimiao Zhao ,&nbsp;Peng Li ,&nbsp;Xiujun Zhang ,&nbsp;Lin Lu ,&nbsp;Yanping Bao","doi":"10.1016/j.lanwpc.2024.101165","DOIUrl":"10.1016/j.lanwpc.2024.101165","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101165"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001597/pdfft?md5=13448fcd8de9f6bcb18888697f8c02bb&pid=1-s2.0-S2666606524001597-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141961579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advocating for rigorous and multifactorial analyses in post-COVID cognitive research","authors":"Qingjia Zeng ,&nbsp;Dan Shan","doi":"10.1016/j.lanwpc.2024.101166","DOIUrl":"10.1016/j.lanwpc.2024.101166","url":null,"abstract":"","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101166"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001603/pdfft?md5=02b623e76e9c29927f656bf110eb8f23&pid=1-s2.0-S2666606524001603-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141961578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug development and evidence for lung cancer targeted therapy in Eastern Asia","authors":"Si-Yang Maggie Liu ,&nbsp;Zhen-Yi Jin ,&nbsp;Jia-Yi Deng ,&nbsp;Si-Min Zhong ,&nbsp;Myung-Ju Ahn ,&nbsp;Hidehito Horinouchi ,&nbsp;Yangqiu Li ,&nbsp;Yi-Long Wu","doi":"10.1016/j.lanwpc.2024.101090","DOIUrl":"10.1016/j.lanwpc.2024.101090","url":null,"abstract":"<div><p>The development of targeted drugs in the Eastern Asia region is going through a flourishing stage. With the continuous advancement of technology and medical research, biotechnology companies and research institutions in the region have made significant progress in cancer field. The Eastern Asian region not only actively participates in clinical trials, but is also committed to developing personalized medical plans to meet the diverse genotypes and phenotypes of patients. The governments and enterprises are increasingly valuing innovation, strengthening international cooperation, and promoting drug development. This paper summarizes the development of genetic testing technology, targeted drugs approval, ongoing promising clinical trials in the field of lung cancer and the important progress made by governments in the Eastern Asian region, and proposed key factors that will contribute to the promising future prospects in the region. The targeted drug market in the Eastern Asian region is expected to drive the medical field forward.</p></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101090"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524000841/pdfft?md5=c1c0a4f472700015aafdba14c4a46a94&pid=1-s2.0-S2666606524000841-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141703294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ear disease, hearing loss, and cognitive outcomes in high school children who were previous participants in a randomized placebo controlled trial of an 11 valent conjugate pneumococcal vaccine administered in infancy","authors":"Andrea S. Miele ,&nbsp;Elisabeth D. Root ,&nbsp;Phyllis Carosone-Link ,&nbsp;Veronica Tallo ,&nbsp;Marilla Lucero ,&nbsp;Diozele Hazel Sanvictores ,&nbsp;Yun Ye ,&nbsp;Kenny H. Chan ,&nbsp;Eric A.F. Simões","doi":"10.1016/j.lanwpc.2024.101128","DOIUrl":"10.1016/j.lanwpc.2024.101128","url":null,"abstract":"<div><h3>Background</h3><p>The WHO estimates that close to 1.7 billion people worldwide have hearing loss; 34 million of whom are children, with 90% residing in low- and middle-income countries. While the effects of ear disease and hearing loss on language, academic, and behavioral development are established, there is remarkably little data on intellectual and other cognitive differences.</p></div><div><h3>Methods</h3><p>Here we report results from an extension of a randomized controlled vaccination trial originally carried out between 2000 and 2004. Primary caregivers completed demographic and household questionnaires. Beginning in 2016, children were followed up for a hearing and ear disease evaluation. Participants also completed extensive cognitive testing, which included the domains of IQ, language, attention and processing speed, visual and visuospatial skills, and learning and memory. The association between ear disease and hearing loss and each of the cognitive outcomes was examined using multivariate linear regression models.</p></div><div><h3>Findings</h3><p>We followed up 8926 children ages 14–19 years old. Children with hearing loss or ear disease had lower socioeconomic status compared to children without. However, even after controlling for a high number of covariates, all levels of ear disease or hearing loss were associated with clinically relevant reductions across all cognitive domains, though effect sizes were small. Even mild ear disease or hearing loss was associated with a −0.15 (95% CI: −0.20, −0.11) and a −0.23 (95% CI: −0.32, −0.14) standard deviation reduction, respectively, in IQ. The effects of ear disease and hearing loss were additive as children with both had the lowest cognitive scores.</p></div><div><h3>Interpretation</h3><p>Untreated ear disease and hearing loss exert measurable effects on cognition that are able to be detected into the teenage years. Early identification of hearing loss and chronic ear disease may have lifelong benefits. Individuals with ear disease and/or hearing loss may require supports and services in addition to those related to speech and language therapy.</p></div><div><h3>Funding</h3><p>The <span>Bill and Melinda Gates Foundation</span> OPP1142570.</p></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101128"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001226/pdfft?md5=f34fa29cf374f159373521d28b93f73f&pid=1-s2.0-S2666606524001226-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142095699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The cost-effectiveness of a co-managed care model for elderly hip fracture patients in China: a modelling study","authors":"Lizheng Xu ,&nbsp;Minghui Yang ,&nbsp;Xinyi Zhang ,&nbsp;Jing Zhang ,&nbsp;Jiusheng He ,&nbsp;Liangyuan Wen ,&nbsp;Xianhai Wang ,&nbsp;Zongxin Shi ,&nbsp;Sanbao Hu ,&nbsp;Fengpo Sun ,&nbsp;Zishun Gong ,&nbsp;Mingyao Sun ,&nbsp;Ke Peng ,&nbsp;Pengpeng Ye ,&nbsp;Ruofei Ma ,&nbsp;Xinbao Wu ,&nbsp;Mingsheng Chen ,&nbsp;Stephen Jan ,&nbsp;Rebecca Ivers ,&nbsp;Maoyi Tian ,&nbsp;Lei Si","doi":"10.1016/j.lanwpc.2024.101149","DOIUrl":"10.1016/j.lanwpc.2024.101149","url":null,"abstract":"<div><h3>Background</h3><p>The clinical effectiveness of multidisciplinary co-managed care for hip fracture patients in China has been demonstrated in a multicenter non-randomized controlled study. This study aims to estimate the cost-effectiveness of the co-managed care.</p></div><div><h3>Methods</h3><p>The study is based on a multicenter clinical trial (n = 2071) in China. We developed a state transition microsimulation model to estimate the cost-effectiveness of the co-managed care compared with usual care for hip fracture patients from healthcare system perspective. The costs incorporated into the model included hospitalization costs, post-discharge expenses, and secondary fracture therapy costs. Effectiveness was measured using quality-adjusted life years (QALYs). Costs and effects were discounted at 5% annually. A simulation cycle length of 1-year and a lifetime horizon were employed. The cost-effectiveness threshold was established at USD 37,118. To address uncertainties, one-way deterministic sensitivity analysis and probabilistic sensitivity analysis were conducted.</p></div><div><h3>Findings</h3><p>In the base case analysis, the co-managed care group had a lifetime cost of USD 31,571 and achieved an effectiveness of 3.22 QALYs, whereas the usual care group incurred a cost of USD 27,878 and gained 2.85 QALYs. The incremental cost-effectiveness ratio was USD 9981 per QALY gained; thus the co-managed care model was cost-effective. The cost-effectiveness was sensitive to the age of having hip fractures and hospitalization costs in the intervention group.</p></div><div><h3>Interpretation</h3><p>The co-managed care in hip fracture patients represents value for money, and should be scaled up and prioritized for funding in China.</p></div><div><h3>Funding</h3><p>The study is supported by Capital's Funds for <span>Health Improvement and Research</span> (2022-1-2071, 2018-1-2071).</p></div>","PeriodicalId":22792,"journal":{"name":"The Lancet Regional Health: Western Pacific","volume":"49 ","pages":"Article 101149"},"PeriodicalIF":7.6,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666606524001433/pdfft?md5=48fe60fda9a4bc28214a9d5471d74151&pid=1-s2.0-S2666606524001433-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141960059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}